首页 | 本学科首页   官方微博 | 高级检索  
     

肺癌脑转移立体定向放疗后MRI变化及对近期疗效评价影响
引用本文:李祥攀,肖建平,陈秀军,张红梅,姜雪松,张烨,徐英杰,李晔雄. 肺癌脑转移立体定向放疗后MRI变化及对近期疗效评价影响[J]. 中华放射肿瘤学杂志, 2014, 23(1): 40-42. DOI: 10.3760/cma.j.issn.1004-4221.2014.01.011
作者姓名:李祥攀  肖建平  陈秀军  张红梅  姜雪松  张烨  徐英杰  李晔雄
作者单位:10002l 北京协和医学院 中国医学科学院肿瘤医院放疗科[李祥攀(现单位武汉大学人民医院肿瘤科)、肖建平、陈秀军(现单位山东大学齐鲁医院)、姜雪松(现单位江苏省肿瘤医院)、张烨、徐英杰、李晔雄],影像科(张红梅)
基金项目:北京希望马拉松专项基金(LC2008A03);卫生部临床学科重点项目(136)
摘    要:
目的 评价肺癌脑转移SRT后MRI变化及对RECIST下疗效的影响。方法 回顾分析SRT的31例肺癌脑转移病例的60个病灶,评价疗后MRI表现及按RECIST记录的疗效。结果60个病灶SRT后MRI评价如下:(1)14个病灶复发,其中8个结节状强化增强、5个均匀强化、1个不均匀强化;(2)11个病灶(18%)为可疑进展,其中均匀强化5个、不均匀强化3个、厚壁强化2个、结节状强化1个;(3) 35个病灶控制,其中19个体积缩小或消失,10个体积和疗前变化不明显,6个较疗前体积增大;(4)有效率为76.7%(可疑进展+控制病灶)。RECIST评价结果为15个病灶CR (25%)、9个病灶PR (15%)、12个病灶SD (20%)、24个病灶PD (40%),有效率为40%。结论 肺癌脑转移SRT后影像学表现多样,且18%病灶难以根据MRI变化判断性质;RECIST低估了近期疗效。

关 键 词:肺肿瘤转移  脑/立体定向放射疗法  磁共振成像  实体瘤疗效评价标准  
收稿时间:2013-09-11

Evaluation of MRI findings and short-term outcome in lung cancer patients with brain metastases after stereotactic radiotherapy
Li Xiangpan,Xiao Jianping,Chen Xiujun,Zhang Hongmei,Jiang Xuesong,Zhang Ye,Xu Yingjie,Li Yexiong.. Evaluation of MRI findings and short-term outcome in lung cancer patients with brain metastases after stereotactic radiotherapy[J]. Chinese Journal of Radiation Oncology, 2014, 23(1): 40-42. DOI: 10.3760/cma.j.issn.1004-4221.2014.01.011
Authors:Li Xiangpan  Xiao Jianping  Chen Xiujun  Zhang Hongmei  Jiang Xuesong  Zhang Ye  Xu Yingjie  Li Yexiong.
Affiliation:Department of Radiation Oncology, Cancer Hospital (institute), Chinese Academy of Medical Science, Peking Union Medical College, Beijing 10021,China
Abstract:
Objective To evaluate the treatment outcomes in lung cancer patients with brain metastases (BM) after stereotactic radiotherapy (SRT) according to magnetic resonance imaging (MRI) findings and the Response Evaluation Criteria In Solid Tumors (RECIST). Methods A retrospective analysis was performed on 31 lung cancer patients with 60 BM lesions who were treated with SRT. Tumor responses were evaluated according to MRI findings and the RECIST. Results The MRI after SRT showed that (1) 14 lesions recurred, with nodular enhancement in 8 lesions, homogeneous enhancement in 5 lesions, and inhomogeneous enhancement in 1 lesion;(2) 11 lesions (18%) had suspected progression, with homogeneous enhancement in 5 lesions, inhomogeneous enhancement in 3 lesions, peripheral enhancement in 2 lesions, and nodular enhancement in 1 lesion;(3) 35 lesions were controlled, with decreased volume or disappearance in 19 lesions, insignificant volume change in 10 lesions, and increased volume in 6 lesions;(4) the overall response rate was 76.7%(suspected progression+ controlled). According to the RECIST, 15 lesions (25%) achieved a complete response (CR), 9 lesions (15%) achieved a partial response (PR), 12 lesions (20%) had stable disease, and 24 lesions (40%) had progressive disease, and the response rate (CR+PR) was 40%. Conclusions There are various MRI findings for brain metastases in lung cancer patients after SRT, and 18% of the lesions are difficult to evaluate by MRI. RECIST underestimates the short-term effect of SRT.
Keywords:Lung neoplasm metastases/stereotactic radiotherapy  Magnetic resonance imaging  Response evaluation criteria in solid tumor
点击此处可从《中华放射肿瘤学杂志》浏览原始摘要信息
点击此处可从《中华放射肿瘤学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号